학술논문
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (g BRCA 1/2+) pathogenic variants: SWOG S2001.
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS4198-TPS4198, 1p
Subject
Language
ISSN
0732183X